Results 51 to 60 of about 4,266 (228)

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures [PDF]

, 2020
Background:Romosozumab is a bone-forming antibody that increases bone formation and decreases bone resorption. We conducted a double-blinded, randomized, phase-2, dose-finding trial to evaluate the effect of romosozumab on the clinical outcomes of open ...
Schemitsch E.H., Miclau T., Karachalios T., Nowak L.L., Sancheti P., Poolman R.W., Caminis J., Daizadeh N., Dent-Acosta R.E., Egbuna O., Chines A., Maddox J., Grauer A., Bhandari M.
core   +2 more sources

A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab

, 2022
Romosozumab is a novel drug for the treatment of osteoporosis. The adverse reactions of romosozumab still need to be explored. The FDA Adverse Event Reporting System (FAERS) provides an enormous dataset for adverse events (AEs) analysis.
Xiaoxia Yu (3752608), Guanghui Chen (316677), Zepeng Chen (8193531), Ming Li (91180), Shuzhen Li (501350), Junyan Wu (4717161), Lin Huang (288599), Yuxi Li (3939713), Kaifeng Qiu (4717164)   +8 more
core   +1 more source

ROMosozumab early experience in female patients with severe osteoporosis in an Italian real-world setting, the ROMEO study. [PDF]

Osteoporos Int
The impact of romosozumab on the bone mineral density surrogate threshold effect (BMD-STE) in postmenopausal women with severe osteoporosis is unknown. Significant BMD gains with romosozumab were observed and 60% of patients achieved the BMD-STE at month
Adami G, Bartezaghi M, Montanari F, Piccinelli A, Pollastri F, Mastropaolo F, Giorgio F, Benini C, Fassio A, Rossini M, Gatti D, Fornari R, Viapiana O.   +12 more
europepmc   +2 more sources

Romosozumab efficacy and safety in European patients enrolled in the FRAME trial

, 2022
UNLABELLED: In this post hoc analysis, we assessed romosozumab efficacy and safety in European patients enrolled in FRAME. Romosozumab treatment through 12 months, followed by denosumab for a further 24 months, resulted in early and sustained risk ...
Hofbauer, Lorenz C., Gielen, Evelien, Lakatos, Peter, Czerwinski, Edward, Timoshanko, Jen, Gimeno, Esteban Jodar, Ferrari, Serge, Ferrari, Serge Livio, Oates, Mary, Hofbauer, Lorenz C, Fahrleitner-Pammer, Astrid, Libanati, Cesar, Langdahl, Bente, Wang, Zhenxun   +13 more
core   +1 more source

Osteoporosis clinical practice guideline: romosozumab for treating severe osteoporosis – an update by the Egyptian Academy of Bone Health

Egyptian Rheumatology and Rehabilitation, 2022
Background This is a Clinical Practice Guideline update released by the Egyptian Academy of Bone Health and Metabolic Bone Diseases. It does not replace the clinical practice guidelines published for the treatment of osteoporosis in 2021, but it entails ...
Yasser El Miedany, Naglaa Ali Gadallah, Mathias Toth, Waleed Hassan, Maha Elgaafary, Mohamed Hassan, Mervat Eissa, Sally Saber, Walaa Elwakil, Safaa Mahran   +9 more
doaj   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis. [PDF]

Arthritis Rheumatol
Objective Transition from long‐term denosumab (Dmab) to parathyroid hormone‐analogs or romosozumab (Romo) might expose patients to the risk of the so‐called rebound phenomenon. Adding Romo to Dmab might represent an option in patients experiencing a fracture while on Dmab.
Adami G, Pollastri F, Fassio A, Montanari F, Piccinelli A, Benini C, Pasetto E, Dartizio C, Gatti D, Rossini M, Viapiana O.   +10 more
europepmc   +2 more sources

Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report

Medicina, 2022
Pregnancy- and lactation-associated osteoporosis (PLO) is a rare type of premenopausal osteoporosis that occurs mainly in the third trimester or immediately after delivery; one of its most common symptoms is back pain caused by a vertebral fracture.
Yoichi Kaneuchi, Masumi Iwabuchi, Michiyuki Hakozaki, Hitoshi Yamada, Shin-ichi Konno   +4 more
doaj   +1 more source

Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023

Aging Clinical and Experimental Research
This study aims to analyze adverse drug events (ADE) related to romosozumab from the second quarter of 2019 to the third quarter of 2023 from FAERS database. The ADE data related to romosozumab from 2019 Q2 to 2023 Q3 were collected.
Luyu Liu, Shaobo Wu, Liangliang Wei, Zhihao Xia, Jiajia Ji, Dageng Huang   +5 more
semanticscholar   +1 more source

Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study

Bone Reports, 2021
Real-world data on the new anti-sclerostin antibody drug, romosozumab, remain scarce. There is a strong need to accumulate and analyze data on romosozumab treatment for such conditions as osteoporosis.
Tomonori Kobayakawa, Takako Suzuki, Masaki Nakano, Makoto Saito, Akiko Miyazaki, Jun Takahashi, Yukio Nakamura   +6 more
doaj   +1 more source

Romosozumab in osteoporosis: yesterday, today and tomorrow

, 2023
Osteoporosis is a systemic bone disease characterized by low bone mass, microarchitectural deterioration, increased bone fragility, and fracture susceptibility. It commonly occurs in older people, especially postmenopausal women.
Guangbin Wang, Zhun Wen, Lei Li, Dong Wu
core   +1 more source